Gene: PLBD1
Official Full Name: phospholipase B domain containing 1provided by HGNC
Gene Summary: Predicted to enable phospholipase activity. Predicted to be involved in phospholipid catabolic process. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO15097 | PLBD1 Knockout cell line (HeLa) | Human | PLBD1 | 1:3~1:6 | Negative | Online Inquiry |
KO15098 | PLBD1 Knockout cell line (A549) | Human | PLBD1 | 1:3~1:4 | Negative | Online Inquiry |
PLBD1 Gene Knockout Cell Lines are specialized cellular models engineered to eliminate the expression of the PLBD1 gene, which encodes for phospholipase B domain-containing protein 1. These knockout cell lines serve as valuable tools in molecular biology and genetic research, allowing scientists to study the phenotypic consequences of PLBD1 deficiency. By utilizing CRISPR/Cas9 gene-editing technology, these cell lines enable precise modifications, ensuring high fidelity in gene disruption and paving the way for investigating the role of PLBD1 in various biological processes.
The primary mechanism underlying the functionality of PLBD1 knockout cell lines revolves around the complete absence or significant reduction of PLBD1 activity, which is integral to membrane phospholipid metabolism and cellular signaling pathways. Researchers can utilize these models to unravel the contributions of PLBD1 to cellular functions such as inflammation, immune responses, and apoptosis, thus elucidating its role in disease pathways, including cancer and metabolic disorders.
In both research and clinical settings, PLBD1 Gene Knockout Cell Lines are pivotal for high-throughput screening, drug discovery, and the development of targeted therapies. They offer insights into gene function and regulation, providing a platform for advancing therapeutic strategies for conditions linked to PLBD1 abnormality. Compared to traditional knockdown methods, these gene knockout models deliver more durable and complete gene disruption, thereby offering clearer insights into gene function.
Furthermore, the unique advantage of our PLBD1 knockout cell lines lies in their reliability and reproducibility, which are critical for generating consistent data across experiments. Researchers, clinicians, and therapeutic developers will find value in using these models to propel their studies forward, with the potential to significantly impact the understanding of PLBD1-related pathologies.
Our company's expertise in cellular biology and gene editing technologies assures that each product is developed with the highest quality standards in mind. This aligns with our mission to advance scientific research with cutting-edge tools, ultimately leading to discoveries that enhance human health.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.